Where now for the management of osteoporosis?
Osteoporosis is a metabolic bone disorder, leading to bone fragility and fracture. Recent guidance from the National Institute for Clinical Excellence (NICE) emphasizes the importance of secondary prevention of fragility fractures in postmenopausal women. What impact can the expanding range of treatments make on the growing and costly burden of osteoporosis?
Fogelman
Ignac
I
Guy's, King's and St Thomas' School of Medicine, Guy's Hospital, London SE1 9RT.
D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011960:Receptors, Estrogen / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D004164:Diphosphonates; D009942:Organometallic Compounds; D010281:Parathyroid Hormone; D011960:Receptors, Estrogen; D013876:Thiophenes; C081587:strontium ranelate; D014807:Vitamin D; D002118:Calcium